KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Account Payables (2016 - 2025)

BeOne Medicines (ONC) has disclosed Change in Account Payables for 11 consecutive years, with $87.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 19.22% to $87.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $79.8 million, a 34.29% decrease, with the full-year FY2025 number at $79.8 million, down 34.29% from a year prior.
  • Change in Account Payables was $87.2 million for Q4 2025 at BeOne Medicines, up from $28.5 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $108.0 million in Q4 2024 to a low of -$73.2 million in Q1 2021.
  • A 5-year average of $11.9 million and a median of $8.0 million in 2022 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 1192.5% in 2024; the steepest drop was 337.19% in 2024.
  • BeOne Medicines' Change in Account Payables stood at $32.4 million in 2021, then crashed by 126.42% to -$8.6 million in 2022, then fell by 15.51% to -$9.9 million in 2023, then skyrocketed by 1192.5% to $108.0 million in 2024, then dropped by 19.22% to $87.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Change in Account Payables are $87.2 million (Q4 2025), $28.5 million (Q3 2025), and -$4.3 million (Q2 2025).